



Phylogica Broker Meets Biotech – Perth (PYC:ASX)

**Harnessing biodiversity for peptide
therapeutics**

Disclaimer

The purpose of the presentation is to provide an update of the business of Phylogica Limited (ASX:PYC) ['Phylogica']. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Phylogica and should not be relied upon as an independent source of information. Please contact Phylogica and/or refer to the Company's website for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Phylogica's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Phylogica's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by Phylogica. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

About Phylogica

- Owns unique proprietary class of peptide therapeutics (Phylomers®)
 - Peptide market forecast: \$25B by 2018
- Extensive & mature IP estate with multiple granted patents
- **Game changing:** ‘Best-in-Class’ peptides for delivering drugs inside cells
- ‘Discovery Alliance’ business model for rapid revenue growth
 - *Generated >\$5.8M in discovery alliance income in <5 years*




Corporate overview


- **PYC Share Price:** 1.7c
- **Market Cap:** \$17m
- **Stock Tightly Held:** >50% stock owned by top 15 shareholders
- **Strong cash position:**
 - Successful \$6.1m cap raise Jan 2014
 - Cash at 30 Jun: \$3,718,659
 - R&D tax rebate + forecast revenues extends cash runway to 2015

Discovery partnership model

- Fee-for-service model generates revenues to achieve *Cash Sustainability*
- Drug discovery engine provides multiple early-stage partnership/discovery opportunities
- Alliance revenues used to subsidise in-house oncology program




Partnerships: focus on intracellular delivery of biologics



PHYLOGICA

Partnerships accelerate platform development




- Phylogica partnerships have driven major platform advances and generated novel IP




Technology Introduction

Phylomer peptides: sourced from nature




Using Phylomers to address an unmet need

Market for Therapeutic Drugs



Small molecule drugs:

- Nonspecific
- Side effects
- Cell penetrating!




Biologics:

- Specific drug delivery
- Reduced toxicity
- No cell penetration


Majority of drug targets are inside cells

Intracellular Drug Targets




- How do we get smart drugs inside cells?

Peptides: the best of both worlds




Cell Penetrating Phylomer (CPPs): delivering biologics cargoes inside cells




Potential to expand the druggable landscape by >10-fold!!

The Problem: Drugs are trapped in endosomes




The Solution: PYC's Endosomal Escape Trap



- Phylogica's endosome escape trap for capture of novel cell penetrating Phylomers

'Best-in-class' Phylomers for delivering drugs inside cells



Phylomers improve intracellular delivery 25 to 50-fold.

Focus: Phylogica's Integrated Drug Discovery Solution

1

Endosomal escape


Cell Penetrating
Phylomers



2

Phylomer Discovery Engine

Phylomer Smart
Drugs



Disruptive technology

10X expansion
in druggable
landscape



Developing Phylomer drugs to treat cancer

- Unmet need for drugs against breast cancer targets intractable to conventional therapies
- Phylogica's platform accelerates path to drug discovery
- Rapid access to high-value commercial inflexion points

Upcoming commercial milestones

- **Discovery Partnerships**

- Genentech II (2014/15)
- New discovery alliances

- **Oncology programme**

- **Early 2015:** *In vitro* data – Key value inflexion, early-stage partnering opportunity.
- **Late 2015:** *In vivo* data - Licensing opportunity

Phylogica: well-positioned to return value for investors

**Addressing unmet need to deliver smart drugs
inside cells**

**Platform validated by
multiple partnerships**

Access to multiple revenue streams

Cash/Capital Efficiency

Contact Details

Dr. Richard Hopkins
Chief Executive Officer
Tel: +61 8 9489 7777
Fax: +61 8 9489 7700
Mobile: +61 405 656 868
richardh@phylogica.com

Dr. Paul Watt
Chief Scientific Officer
Tel: +61 8 9489 7777
Fax: +61 8 9489 7700
Mobile: +61 421 550 213
paulw@phylogica.com



www.phylogica.com